Lymph node ratio in relation to the survival benefit of immediate breast reconstruction in node-positive breast cancer: A population-based cohort study.

e12686 Background: Immediate breast reconstruction (IBR) after mastectomy is increasingly performed, yet its survival impact in node-positive breast cancer remains uncertain and may vary by axillary tumor burden. Lymph node ratio (LNR) may better reflect nodal metastatic extent than conventional N staging. Methods: We identified 14,376 female patients (2010–2017) with non-metastatic, node-positive breast cancer who underwent mastectomy with or without IBR. Propensity score matching yielded 4,050 matched pairs. Multivariable Cox models with interaction terms assessed whether LNR modified the association between IBR and overall survival (OS) or breast cancer–specific survival (BCSS). LNR thresholds for loss of IBR benefit were identified using a stepwise algorithm. Results: A significant interaction between IBR and LNR was observed for both OS (interaction HR = 1.494, 95% CI: 1.111–2.009; p = 0.0078) and BCSS (HR = 1.404, 95% CI: 1.013–1.946; p = 0.0415). IBR was associated with improved OS in patients with LNR ≤ 0.3429 (HR = 0.76, 95% CI: 0.68–0.85; p < 0.001) but not in those with LNR > 0.3429 (HR = 1.02, 95% CI: 0.89–1.17; p = 0.78). For BCSS, the benefit threshold was lower (LNR ≤ 0.1842; HR = 0.82, 95% CI: 0.72–0.93; p = 0.002). Traditional N staging showed inferior discrimination. Conclusions: LNR significantly modifies the survival benefit of IBR in node-positive breast cancer. Incorporating LNR into preoperative decision-making may optimize patient selection for reconstruction. A nomogram integrating LNR and clinicopathologic factors was developed to support individualized risk prediction. Interaction analysis of LNR and surgery type on survival before and after PSM (Cox model). Before or After PSM cohort Before PSMOS Before PSMBCSS After PSMOS After PSMBCSS Model* HR (95% CI), p HR (95% CI) HR (95% CI) HR (95% CI) Model 1 1.628 (1.273–2.082), p < 0.0001 1.422 (1.086–1.863), p = 0.0105 1.416 (1.052–1.906), p = 0.0218 1.327 (0.958–1.839), p = 0.0890 Model 2 1.635 (1.278–2.090), p < 0.0001 1.460 (1.114–1.914), p = 0.0062 1.418 (1.053–1.910), p = 0.0216 1.343 (0.968–1.864), p = 0.0776 Model 3 1.583 (1.239–2.024), p = 0.0002 1.402 (1.070–1.836), p = 0.0141 1.466 (1.089–1.975), p = 0.0118 1.388 (1.000–1.926), p = 0.0500 Model 4 1.634 (1.281–2.085), p < 0.0001 1.433 (1.095–1.874), p = 0.0087 1.497 (1.113–2.013), p = 0.0076 1.406 (1.015–1.949), p = 0.0405 Model 5 1.626 (1.274–2.074), p < 0.0001 1.426 (1.090–1.865), p = 0.0096 1.494 (1.111–2.009), p = 0.0078 1.404 (1.013–1.946), p = 0.0415

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2026-05-28
DOI
https://doi.org/10.1200/jco.2026.44.16_suppl.e12686
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lymph node ratio in relation to the survival benefit of immediate breast reconstruction in node-positive breast cancer: A population-based cohort study.

宗祥云, Qianrui Xu, Zhu Y
Journal of Clinical Oncology
Breast Cancer Treatment Studies
article

Lymph node ratio in relation to the survival benefit of immediate breast reconstruction in node-positive breast cancer: A population-based cohort study.

宗祥云, Qianrui Xu, Zhu Y
article en

Abstract

e12686 Background: Immediate breast reconstruction (IBR) after mastectomy is increasingly performed, yet its survival impact in node-positive breast cancer remains uncertain and may vary by axillary tumor burden. Lymph node ratio (LNR) may better reflect nodal metastatic extent than conventional N staging. Methods: We identified 14,376 female patients (2010–2017) with non-metastatic, node-positive breast cancer who underwent mastectomy with or without IBR. Propensity score matching yielded 4,050 matched pairs. Multivariable Cox models with interaction terms assessed whether LNR modified the association between IBR and overall survival (OS) or breast cancer–specific survival (BCSS). LNR thresholds for loss of IBR benefit were identified using a stepwise algorithm. Results: A significant interaction between IBR and LNR was observed for both OS (interaction HR = 1.494, 95% CI: 1.111–2.009; p = 0.0078) and BCSS (HR = 1.404, 95% CI: 1.013–1.946; p = 0.0415). IBR was associated with improved OS in patients with LNR ≤ 0.3429 (HR = 0.76, 95% CI: 0.68–0.85; p < 0.001) but not in those with LNR > 0.3429 (HR = 1.02, 95% CI: 0.89–1.17; p = 0.78). For BCSS, the benefit threshold was lower (LNR ≤ 0.1842; HR = 0.82, 95% CI: 0.72–0.93; p = 0.002). Traditional N staging showed inferior discrimination. Conclusions: LNR significantly modifies the survival benefit of IBR in node-positive breast cancer. Incorporating LNR into preoperative decision-making may optimize patient selection for reconstruction. A nomogram integrating LNR and clinicopathologic factors was developed to support individualized risk prediction. Interaction analysis of LNR and surgery type on survival before and after PSM (Cox model). Before or After PSM cohort Before PSMOS Before PSMBCSS After PSMOS After PSMBCSS Model* HR (95% CI), p HR (95% CI) HR (95% CI) HR (95% CI) Model 1 1.628 (1.273–2.082), p < 0.0001 1.422 (1.086–1.863), p = 0.0105 1.416 (1.052–1.906), p = 0.0218 1.327 (0.958–1.839), p = 0.0890 Model 2 1.635 (1.278–2.090), p < 0.0001 1.460 (1.114–1.914), p = 0.0062 1.418 (1.053–1.910), p = 0.0216 1.343 (0.968–1.864), p = 0.0776 Model 3 1.583 (1.239–2.024), p = 0.0002 1.402 (1.070–1.836), p = 0.0141 1.466 (1.089–1.975), p = 0.0118 1.388 (1.000–1.926), p = 0.0500 Model 4 1.634 (1.281–2.085), p < 0.0001 1.433 (1.095–1.874), p = 0.0087 1.497 (1.113–2.013), p = 0.0076 1.406 (1.015–1.949), p = 0.0405 Model 5 1.626 (1.274–2.074), p < 0.0001 1.426 (1.090–1.865), p = 0.0096 1.494 (1.111–2.009), p = 0.0078 1.404 (1.013–1.946), p = 0.0415

Journal of Clinical OncologyVol. 44(16_suppl)
Shanghai Jiao Tong University (CN), Shanghai Sixth People's Hospital (CN)
Gender equality
Openalex Percentile: Top 7%
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.